Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,263 across all filing types
Latest filing 2022-07-06 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
This has reference to your email dated July 6, 2022 bearing reference no. L/SURV/ONL/PV/NP/ 2022-2023 / 98 on the captioned subject. We wish to inform you that we have no information/announcement .
Regulatory Filings Classification · 95% confidence The document is a letter from the company to a stock exchange regulatory body (BSE Limited) responding to an inquiry about unusual trading volume. It states that the company has no pending announcements that could affect the stock price or volume. The letter references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The document is short (1118 characters) and is a regulatory communication rather than a financial report or announcement of a report. It does not contain financial data, management changes, voting results, or other specific report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications and compliance-related filings.
2022-07-06 English
Spurt in Volume
Regulatory Filings Classification · 95% confidence The document is a letter from AstraZeneca Pharma India Limited to the National Stock Exchange of India regarding an inquiry about an increase in trading volume. The company states it has no information or announcements that could explain the volume change. The letter references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, indicating it is a regulatory communication. The document is short (1113 characters) and does not contain any financial data, report content, or detailed disclosures. It is not a financial report, earnings release, or management discussion. It is a regulatory filing responding to a surveillance query, fitting the category of Regulatory Filings (RNS).
2022-07-06 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Capital/Financing Update Classification · 95% confidence The document is a short letter dated July 1, 2022, addressed to stock exchanges (BSE and NSE) informing them about a scheduled interaction with an analyst/investor. It references Regulation 30 of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content is an announcement of an upcoming investor meeting, not a financial report or detailed presentation. The document length is only 1345 characters, indicating it is a brief notice rather than a full report. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to investor relations and scheduled interactions with analysts/investors.
2022-07-01 English
Pursuant to the Regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we hereby inform that an interaction with analyst / investor is scheduled to ....
Regulatory Filings Classification · 95% confidence The document is a short letter dated July 1, 2022, addressed to stock exchanges (BSE and NSE) informing them about a scheduled interaction with an analyst/investor. It references Regulation 30 of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content is an announcement of an upcoming event (investor interaction) rather than a financial report or detailed presentation. The document length is only 1345 characters, indicating it is a brief notice rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the category for general regulatory announcements and compliance disclosures that do not fit other specific categories.
2022-07-01 English
Record Date
Notice of Dividend Amount Classification · 100% confidence The document is a short official communication addressed to stock exchanges regarding the record date for payment of a final dividend for the financial year 2021-22. It specifies the record date and the expected payment date of the dividend. There are no financial statements, detailed analysis, or other report content. The document is an announcement about dividend payment details, which fits the category of Notice of Dividend Amount filings.
2022-06-27 English
Further to our intimation dated May 26, 2022, we wish to inform that the Record Date for determining the entitlement of the shareholders for the payment of the Final Dividend for financial ....
Notice of Dividend Amount Classification · 100% confidence The document is a short official communication addressed to stock exchanges regarding the record date for payment of a final dividend for the financial year 2021-22. It specifies the date for determining shareholder entitlement and the expected payment date of the dividend. There is no detailed financial data or report content, only an announcement related to dividend payment details. The document length is short (1124 characters), and it serves as a notification rather than a full report. Therefore, it fits the category of Notice of Dividend Amount (DIV).
2022-06-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.